Rosenke Kyle, Meade-White Kimberly, Letko Michael, Clancy Chad, Hansen Frederick, Liu Yanan, Okumura Atsushi, Tang-Huau Tsing-Lee, Li Rong, Saturday Greg, Feldmann Friederike, Scott Dana, Wang Zhongde, Munster Vincent, Jarvis Michael A, Feldmann Heinz
Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
bioRxiv. 2020 Sep 27:2020.09.25.314070. doi: 10.1101/2020.09.25.314070.
Following emergence in late 2019, SARS-CoV-2 rapidly became pandemic and is presently responsible for millions of infections and hundreds of thousands of deaths worldwide. There is currently no approved vaccine to halt the spread of SARS-CoV-2 and only very few treatment options are available to manage COVID-19 patients. For development of preclinical countermeasures, reliable and well-characterized small animal disease models will be of paramount importance. Here we show that intranasal inoculation of SARS-CoV-2 into Syrian hamsters consistently caused moderate broncho-interstitial pneumonia, with high viral lung loads and extensive virus shedding, but animals only displayed transient mild disease. We determined the infectious dose 50 to be only five infectious particles, making the Syrian hamster a highly susceptible model for SARS-CoV-2 infection. Neither hamster age nor sex had any impact on the severity of disease or course of infection. Finally, prolonged viral persistence in interleukin 2 receptor gamma chain knockout hamsters revealed susceptibility of SARS-CoV-2 to adaptive immune control. In conclusion, the Syrian hamster is highly susceptible to SARS-CoV-2 making it a very suitable infection model for COVID-19 countermeasure development.
2019年末出现后,严重急性呼吸综合征冠状病毒2(SARS-CoV-2)迅速成为大流行病,目前在全球造成了数百万例感染和数十万例死亡。目前尚无批准用于阻止SARS-CoV-2传播的疫苗,且仅有极少数治疗方案可用于治疗新型冠状病毒肺炎(COVID-19)患者。对于临床前应对措施的研发而言,可靠且特征明确的小动物疾病模型至关重要。在此,我们表明将SARS-CoV-2经鼻接种到叙利亚仓鼠体内会持续引发中度支气管间质性肺炎,伴有高病毒肺载量和广泛的病毒脱落,但动物仅表现出短暂的轻度疾病。我们确定半数感染剂量仅为五个感染性颗粒,这使得叙利亚仓鼠成为SARS-CoV-2感染的高度易感模型。仓鼠的年龄和性别对疾病严重程度或感染进程均无任何影响。最后,在白细胞介素2受体γ链敲除仓鼠中病毒的持续存在时间延长,揭示了SARS-CoV-2对适应性免疫控制的敏感性。总之,叙利亚仓鼠对SARS-CoV-2高度易感,使其成为COVID-19应对措施研发非常合适的感染模型。